"[These proteomic tests] ... offer a means to detect neurodegenerative diseases at their earliest stages, allowing physicians to begin treatment at stages which will produce more positive outcomes."

— Steven Rash, CEO of Power3 Medical, discussing the company's ongoing development of blood serum-based protein biomarker tests for Alzheimer's and other diseases, "Power3 banners nearing first definitive Alzheimer's test."